| __timestamp | Arrowhead Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 20140000 |
| Thursday, January 1, 2015 | 34718089 | 37173000 |
| Friday, January 1, 2016 | 40998209 | 48616000 |
| Sunday, January 1, 2017 | 32022880 | 108488000 |
| Monday, January 1, 2018 | 19110051 | 244622000 |
| Tuesday, January 1, 2019 | 26556257 | 287000000 |
| Wednesday, January 1, 2020 | 52275890 | 354000000 |
| Friday, January 1, 2021 | 80981000 | 186000000 |
| Saturday, January 1, 2022 | 124431000 | 151000000 |
| Sunday, January 1, 2023 | 90932000 | 232600000 |
| Monday, January 1, 2024 | 98761000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting strategies in cost management.
From 2014 to 2023, Ionis Pharmaceuticals saw a staggering 1,050% increase in SG&A expenses, peaking in 2020. This surge reflects their aggressive expansion and investment in administrative capabilities. In contrast, Arrowhead Pharmaceuticals experienced a more moderate 300% rise, with a notable spike in 2022, indicating a strategic pivot towards scaling operations.
Interestingly, 2024 data for Ionis is missing, suggesting potential reporting delays or strategic shifts. As these companies navigate the complexities of the biotech landscape, their SG&A trends offer valuable insights into their operational priorities and market positioning.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE